Methylenetetrahydrofolate reductase C677T polymorphism predicts response and time to progression to gemcitabine-based chemotherapy for advanced non-small cell lung cancer in a Chinese Han population

• Published in: Journal of Zhejiang University. B. Science Vol. 14; no. 3; pp. 207 - 215
• Main Authors: Hong, Wei, Wang, Kai, Zhang, Yi-ping, Kou, Jun-yan, Hong, Dan, Su, Dan, Mao, Wei-min, Yu, Xin-min, Xie, Fa-jun, Wang, Xiao-jian
• Format: Journal Article
• Language: English
• Published: Heidelberg SP Zhejiang University Press 01.03.2013; Springer Nature B.V; Zhejiang University Press
• Subjects: Adult; Aged; Antimetabolites, Antineoplastic - therapeutic use; Biomedical and Life Sciences; Biomedicine; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - epidemiology; Carcinoma, Non-Small-Cell Lung - genetics; China - epidemiology; Deoxycytidine - analogs & derivatives; Deoxycytidine - therapeutic use; Female; Genetic Markers - genetics; Genetic Predisposition to Disease - epidemiology; Genetic Predisposition to Disease - genetics; Humans; Lung Neoplasms - drug therapy; Lung Neoplasms - epidemiology; Lung Neoplasms - genetics; Male; Methylenetetrahydrofolate Reductase (NADPH2) - genetics; Middle Aged; Outcome Assessment (Health Care) - methods; Outcome Assessment (Health Care) - statistics & numerical data; Polymorphism, Single Nucleotide - genetics; Prevalence; Reproducibility of Results; Retrospective Studies; Sensitivity and Specificity; Treatment Outcome; 临床; 化疗; 治疗; 肺癌; 肿瘤; China; Methylenetetrahydrofolate reductase; Excision repair cross-complementation group 1; Single nucleotide polymorphism; Gemcitabine; R734.2; Non-small cell lung cancer
• ISSN: 1673-1581; 1862-1783
• DOI: 10.1631/jzus.B1200101

Objective： The aim of this study was to evaluate the association between the methylenetetrahydrofolate reductase （MTHFR） C677T excision repair cross-complementation group 1 （ERCC1） genetic polymorphisms and the clinical efficacy of gemcitabine-based chemotherapy in advanced non-small cell lung cancer （NSCLC）. Methods： A total of 135 chemonaive patients with unresectable advanced NSCLC were treated with gemcitabine/platinum regi- mens. The polymorphisms of MTHFR C677T, ERCC1 C8092A, and ERCC1 Cl18T were genotyped using the TaqMan methods. Results： The overall response rate was 28.9%. Patients with MTHFR CC genotype had a higher rate of objective response than patients with variant genotype （TT or CT） （41.2% versus 19.1%, P=0.01 ）. Median time to progression （TTP） of patients with MTHFR CC genotype was longer than that of patients with variant genotype （7.6 months versus 5.0 months, P=0.003）. No significant associations were obtained between ERCC1 C118T and C8092A polymorphisms and both response and survival. Conclusions： Our data suggest the value of MTHFR C677T polymorphism as a possible predictive marker of response and TTP in advanced NSCLC patients treated with gemcitabine/platinum.